Filing Details
- Accession Number:
- 0001127602-12-008916
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-03-01 16:28:36
- Reporting Period:
- 2012-02-28
- Filing Date:
- 2012-03-01
- Accepted Time:
- 2012-03-01 16:28:36
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 884731 | Ariad Pharmaceuticals Inc | ARIA | Biological Products, (No Disgnostic Substances) (2836) | 223106987 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1242986 | L David Berstein | C/O Ariad Pharmaceuticals, Inc. 26 Landsdowne Street Cambridge MA 02139 | Senior Vp, Chief Ip Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2012-02-28 | 10,200 | $3.90 | 208,456 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2012-02-28 | 1,175 | $4.19 | 209,631 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2012-02-28 | 11,375 | $15.50 | 198,256 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2012-02-28 | 10,200 | $0.00 | 10,200 | $3.90 |
| Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2012-02-28 | 1,175 | $0.00 | 1,175 | $4.19 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2003-08-15 | 2013-08-15 | No | 4 | M | Direct |
| 0 | 2003-06-18 | 2012-06-18 | No | 4 | M | Direct |
Footnotes
- Shares were acquired upon the exercise of outstanding stock options at $3.90 per share.
- Shares were acquired upon the exercise of outstanding stock option at $4.19 per share.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2011.
Billionaire Hedge Funds
